3B Blackbio Dx revenue jumps 47% on diagnostic kit surge
Annual sales hit ₹141.92 cr, with the diagnostics division accounting for most of the growth. Net profit rose 25.6% to ₹59.93 cr.
— 1 earlier story on 3B Blackbio Dx Ltd. →What's new
- Revenue grew 47% to ₹141.92 cr; diagnostics kits led with ₹131.11 cr in sales, up from ₹84.28 cr.
- Net profit rose 25.6% to ₹59.93 cr.
- Board recommended a final dividend of ₹5.00 per share (50% payout on face value).
Why this matters
The numbers are strong, but the story is narrower than they suggest. The diagnostics division drove almost all the topline expansion, and the rationale ties that partly to the Coris Bioconcept integration. The profit growth, while solid, lags revenue growth, hinting at margin pressure.
What we're watching
- Margin trajectory as acquisition integration progresses.
- R&D capitalization impact at the Belgian subsidiary.
- Final dividend payout ratio versus prior years.
The full read
3B Blackbio Dx put up a strong topline for FY26. Revenue surged 47% to ₹141.92 cr, with the diagnostics kits division doing the heavy lifting. That segment's sales jumped to ₹131.11 cr from ₹84.28 cr last year. The rationale notes this growth partly reflects the integration of acquisitions like Coris Bioconcept. Net profit grew 25.6% to ₹59.93 cr, a respectable number but one that noticeably trails the top-line expansion. The board recommended a final dividend of ₹5.00 per share. The open question is how much of this growth is organic versus acquisition-driven, and whether the margin gap between revenue and profit growth narrows next year.
Questions answered
- How much of the revenue growth came from the diagnostics division?
- The diagnostics division revenue rose to ₹131.11 cr from ₹84.28 cr. That increase of about ₹47 cr accounts for nearly all of the company's overall revenue growth.
- Why did profit growth lag revenue growth?
- The rationale doesn't specify the cause, but net profit grew 25.6% on 47% revenue growth. This suggests operating costs or integration expenses grew faster than sales.
- What was the dividend amount and yield?
- The board recommended a ₹5.00 per share final dividend. This represents a 50% payout on the stock's face value.
- What is the significance of the Coris Bioconcept mention?
- The rationale states the diagnostics division growth partly reflects the integration of acquisitions like Coris Bioconcept. This implies inorganic growth contributed to the segment's performance.
- What else did the board discuss?
- The board appointed Ali Jain & Sharma as internal auditors for FY27 and reviewed the capitalization of R&D expenses at its Belgian subsidiary.
Story so far
All notes on 3BBLACKBIO →- 29 May 2026 · 5:12 PM IST 3B Blackbio Dx revenue jumps 47% on diagnostic kit surge
- 1d ago 3B Blackbio Dx posts 47% revenue jump, raises dividend